NCT04836884

Vascular Anomaly Pathology and Genomics Biopsy Study

Validation of Core Biopsy of Vascular Anomalies for Clinical Pathology and Genomics

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to gather information on the safety and effectiveness of core biopsy of vascular anomalies for clinical pathology and clinical genomics studies.

Detailed description

Vascular anomalies or vascular malformations often are treated with minimally invasive sclerotherapy, embolization or ablation based on clinical and imaging features without acquisition of tissue. Over the last two decades there have been significant advancements in the understanding of the genetic basis for various vascular anomalies/malformations, which may guide use of therapies for individualized treatment. As such, given the emergence of novel medications for treatment of vascular anomalies/malformations based on genetic information, acquisition of tissue for pathology and genomic characterization will be increasingly important as treatment of vascular anomalies/vascular malformations moves toward individualized medicine approach.

Conditions

• Vascular Malformations
• Vascular Anomaly
• Hemangioma
• Arteriovenous Malformations
• Venous Malformation
• Klippel Trenaunay Syndrome
• Lymphatic Malformation

Interventions

Type	Name	Description
PROCEDURE	Percutaneous Vascular Anomaly/Malformation Biopsy	US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.

Timeline

• Start date: 2021-04-06
• Primary completion: 2022-01-31
• Completion: 2022-01-31
• First posted: 2021-04-08
• Last updated: 2022-04-21

Locations

1 site across 1 country: United States